Linagliptin Add-on to Insulin Background Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.
Also called NCT02897349
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 206 participants
- Registry
-
NCT02897349
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02897349. Randomized; double masking; primary purpose treatment. Start 2016-09-30 (actual); primary completion 2019-01-11 (actual). Results posted on 2020-01-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Linagliptin Add-on to Insulin Background Therapy
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- placebo
- Intervention (Drug)
- linagliptin
- Intervention (Drug)
- background therapy
- Lead sponsor
- Boehringer Ingelheim
- Collaborator
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02897349- Content hash
b54f4d385dd75ffc09ddb16866ef4742ce33e3923fc8adafa68a807cb37d6701